MXI1 ist ein Gen, das durch das Symbol MXI1 kodiert wird. Im Allgemeinen auch bezeichnet als: Max-interacting protein 1; Max interactor 1; Class C basic helix-loop-helix protein 11; bHLHc11; BHLHC11. MXI1 hat eine Masse von 26.06kDa, eine Aminosäurelänge von 228, und ist an Prostate cancer beteiligt.
Wir bieten 6 antikörper gegen MXI1, aufgewachsen in Kaninchen und Maus, welche geeignet sind für WB, IHC, ICC/IF and FC mit Proben abgeleitet von Human, Maus und Ratte.
Gen- und Proteininformationen
UniProt Zusammenfassung
Transcriptional repressor. MXI1 binds with MAX to form a sequence-specific DNA-binding protein complex which recognizes the core sequence 5'-CAC[GA]TG-3'. MXI1 thus antagonizes MYC transcriptional activity by competing for MAX.
Entrez Zusammenfassung
Expression of the c-myc gene, which produces an oncogenic transcription factor, is tightly regulated in normal cells but is frequently deregulated in human cancers. The protein encoded by this gene is a transcriptional repressor thought to negatively regulate MYC function, and is therefore a potential tumor suppressor. This protein inhibits the transcriptional activity of MYC by competing for MAX, another basic helix-loop-helix protein that binds to MYC and is required for its function. Defects in this gene are frequently found in patients with prostate tumors. Three alternatively spliced transcripts encoding different isoforms have been described. Additional alternatively spliced transcripts may exist but the products of these transcripts have not been verified experimentally.
Gewebespezifität
High levels found in the brain, heart and lung while lower levels are seen in the liver, kidney and skeletal muscle.
Rolle bei Krankheiten
Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
